Trevor R F Smith
Overview
Explore the profile of Trevor R F Smith including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
44
Citations
1191
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Andrade V, Cashman K, Rosenke K, Wilkinson E, Josleyn N, Lynn G, et al.
Commun Med (Lond)
. 2024 Nov;
4(1):253.
PMID: 39609515
Background: We have previously developed a DNA-based vaccine, INO-4500, encoding the Lassa lineage IV glycoprotein precursor. INO-4500, when delivered with electroporation, elicited humoral and cellular responses, and conferred 100% protection...
2.
Patel A, Rosenke K, Parzych E, Feldmann F, Bharti S, Griffin A, et al.
Emerg Microbes Infect
. 2024 Jan;
13(1):2294860.
PMID: 38165394
COVID-19 remains a major public health concern. Monoclonal antibodies have received emergency use authorization (EUA) for pre-exposure prophylaxis against COVID-19 among high-risk groups for treatment of mild to moderate COVID-19....
3.
Andrade V, Maricic I, Kalia R, Jachimowicz L, Bedoya O, Kulp D, et al.
Hum Vaccin Immunother
. 2023 Nov;
19(3):2281733.
PMID: 38012018
Nucleic acid vaccines are designed based on genetic sequences (DNA or mRNA) of a target antigen to be expressed to drive a host immune response. In response to the COVID-19...
4.
Tursi N, Xu Z, Helble M, Walker S, Liaw K, Chokkalingam N, et al.
Front Immunol
. 2023 Mar;
14:1072810.
PMID: 36911698
Cancer immunotherapy has demonstrated great promise with several checkpoint inhibitors being approved as the first-line therapy for some types of cancer, and new engineered cytokines such as Neo2/15 now being...
5.
Hollevoet K, Thomas D, Compernolle G, Vermeire G, De Smidt E, De Vleeschauwer S, et al.
Front Oncol
. 2022 Oct;
12:1017612.
PMID: 36263202
DNA-encoded delivery and expression of antibody therapeutics presents an innovative alternative to conventional protein production and administration, including for cancer treatment. To support clinical translation, we evaluated this approach in...
6.
Parzych E, Du J, Ali A, Schultheis K, Frase D, Smith T, et al.
Nat Commun
. 2022 Oct;
13(1):5886.
PMID: 36202799
Monoclonal antibody therapy has played an important role against SARS-CoV-2. Strategies to deliver functional, antibody-based therapeutics with improved in vivo durability are needed to supplement current efforts and reach underserved...
7.
Gary E, Tursi N, Warner B, Parzych E, Ali A, Frase D, et al.
Cell Rep Med
. 2022 Jul;
3(7):100693.
PMID: 35839767
The global coronavirus disease 2019 (COVID-19) pandemic has claimed more than 5 million lives. Emerging variants of concern (VOCs) continually challenge viral control. Directing vaccine-induced humoral and cell-mediated responses to...
8.
Walters J, Schouest B, Patel A, Reuschel E, Schultheis K, Parzych E, et al.
Vaccine
. 2022 Apr;
40(21):2960-2969.
PMID: 35428500
The enhanced transmissibility and immune evasion associated with emerging SARS-CoV-2 variants demands the development of next-generation vaccines capable of inducing superior protection amid a shifting pandemic landscape. Since a portion...
9.
Konrath K, Liaw K, Wu Y, Zhu X, Walker S, Xu Z, et al.
Cell Rep
. 2022 Jan;
38(5):110318.
PMID: 35090597
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines may target epitopes that reduce durability or increase the potential for escape from vaccine-induced immunity. Using synthetic vaccinology, we have developed rationally...
10.
Kraynyak K, Blackwood E, Agnes J, Tebas P, Giffear M, Amante D, et al.
J Infect Dis
. 2022 Jan;
225(11):1923-1932.
PMID: 35079784
Background: Additional severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines that are safe and effective as primary vaccines and boosters remain urgently needed to combat the coronavirus disease 2019 (COVID-19)...